SCHEMBL3774174

SCHEMBL3774174

CC(C)N1CCN(C(=O)CN2CCN(c3nc4ccccc4s3)CC2)CC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.67
RAB9A P51151 8/20 0.67
LMNA P02545 6/20 0.67
MAPT P10636 5/20 0.67
MAPK1 P28482 2/20 0.61
SMN1; SMN2 Q16637 5/20 0.57
POLB P06746 2/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2D6 P10635 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2C19 P33261 1/20 0.57
TP53 P04637 1/20 0.55
GAA P10253 1/20 0.54
TSHR P16473 2/20 0.53
ALDH1A1 P00352 2/20 0.53
HTT P42858 2/20 0.53
ALOX15 P16050 1/20 0.53
CASP1 P29466 1/20 0.53
HSD17B10 Q99714 1/20 0.53
MEN1 O00255 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14417581 0.84 RAB9A (0.65) NPC1RAB9ALMNAMAPTSMN1; SMN2
SCHEMBL18711500 0.82 NPC1 (0.76) NPC1RAB9ALMNAMAPTMAPK1
SCHEMBL3767690 0.81 NPC1 (0.61) NPC1RAB9ALMNAMAPTMAPK1
SCHEMBL3769788 0.81 NPC1 (0.61) NPC1RAB9ALMNAMAPTMAPK1
SCHEMBL3773400 0.81 NPC1 (0.60) NPC1RAB9ALMNAMAPTMAPK1
SCHEMBL28142588 0.78 RAB9A (0.72) NPC1RAB9ALMNAMAPTMAPK1
SCHEMBL15940856 0.77 NPC1 (0.80) NPC1RAB9ALMNAMAPTMAPK1
SCHEMBL3762814 0.77 MAPT (0.78) LMNAMAPTSMN1; SMN2TP53GAA
SCHEMBL24507962 0.77 NPC1 (0.67) NPC1RAB9ALMNAMAPTMAPK1
SCHEMBL3860850 0.77 MAPK1 (0.71) NPC1RAB9ALMNAMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 NPC1 3462/4885RAB9A 3824/4885LMNA 2902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.